Nachrichten zur Puma Biotechnology Inc. Aktie

Sales of PBYIs sole-marketed drug, Nerlynx, exceeded managements expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.…

Sales of PBYIs sole-marketed drug, Nerlynx exceeded managements expectations in the third quarter. Also, the acquisition of alisertib holds promise.…

Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.…

…

…

…

…

Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity are part of the Zacks Screen of the Week article.…

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.…

Here are four top-performing liquid stocks, Abercrombie & Fitch (ANF), Puma Biotechnology (PBYI), Spotify (SPOT) and Oddity Tech (ODD), which…

Sales of Puma Biotechnologys (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target…

Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.…

…

…

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.…

…

On Puma Biotechnologys (PBYI) first-quarter 2024 earnings call, investors focus is likely to be on the sales performance of its…

…

…

Puma Biotechnologys (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.…

On Puma Biotechnologys (PBYI) fourth-quarter 2023 earnings call, investors focus is likely to be on the sales performance of its…